Oral absorption of peptides/oligonucleotides - how far have we come?

• In: Symposium B4: Oral absorption of biopharmaceuticals revisited on Wednesday, 24 May 2017, 11:15-11:50
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: BRAYDEN, David (University College Dublin, Conway Institute, Dublin, Ireland)
• Co-author(s): David Brayden: Conway Institute, University College Dublin, Dublin, Ireland
  
• Abstract:

  Three oral peptide formulations have reached Phase III trials, with another   ̴20-25 technologies in Phase II.  Tarsa’s (NJ) oral salmon calcitonin (sCT) (TBRIA™) for osteoporosis was submitted in 2015 following a Phase III trial (ORACAL) and comprises an enteric-coated tablet/capsule with sCT and a peptidase inhibitor (citric acid) in vesicles. 

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login